Longevity stocks

Stryker has heavy exposure through its orthopaedics and MedSurg segments, though it is more diversified than ZBH.

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

Regis is a residential aged-care operator and was specifically identified as a beneficiary of the proposed funding changes, making it the most direct listed-company exposure in the set.

NHC directly operates skilled-nursing and senior-living facilities, making its operating margins sensitive to reimbursement, labor and occupancy conditions.

Demant is a hearing-aid manufacturer, and hearing-aid production depends on DSP chips, MEMS microphones, batteries, connectivity components, and related electronics.

CareTrust owns SNF real estate and benefits from contractual rent, but its cash flow ultimately depends on operator ability to cover rent amid reimbursement and labor pressures.

CareTrust REIT, Inc. operates as a self-managed, publicly traded real estate investment trust. The company specializes in the ownership, acquisition, development, and leasing of various healthcare properties, including skilled nursing facilities, seniors' housing complexes, and other related medical real estate. It maintains a broad, nationwide portfolio of assets, all under long-term net lease agreements with an expanding group of reputable operators. CareTrust REIT is actively pursuing strategic growth across the United States, leveraging both external investments and organic expansion opportunities.

GN is also a major incumbent hearing-aid manufacturer and is exposed to OTC substitution away from audiologist-mediated purchasing.

GN is a major incumbent hearing-aid manufacturer and an established participant in the hearables ecosystem. Meta’s clearance raises competitive pressure from a large consumer platform offering self-fitting hearing enhancement through glasses, potentially challenging GN’s traditional device and professional-channel economics.

Sonova is an incumbent hearing-device company with indirect exposure through possible future reductions in hearing-aid demand.

Headquartered in Stäfa, Switzerland, Sonova Holding AG is a leading provider of innovative hearing care solutions for both adults and children. The company's operations are divided into two primary segments: Hearing Instruments and Cochlear Implants. Sonova's extensive offerings include advanced wireless communication devices, rechargeable hearing aids, wireless headsets, speech-enhanced hearables, premium audiophile headphones, microphones, and wireless transmission systems, alongside comprehensive audiological care services. Its renowned hearing aid brands comprise Phonak, Unitron, and Hansaton, while Advanced Bionics is its flagship for cochlear implants. For consumer audio, Sonova offers products under the Sennheiser brand. The company delivers its audiological care through a vast network of around 3,600 clinics and stores operating under various regional names such as AudioNova, Audium, and Boots Hearingcare, among others. Additionally, its products are distributed via independent partners. Sonova boasts a significant international presence, serving markets across the United States, Europe, the Middle East, Africa, and the Asia Pacific. Founded in 1947, the company was formerly known as Phonak Holding AG before officially changing its name to Sonova Holding AG in August 2007.

Outlook Therapeutics is a development-stage biopharmaceutical firm whose entire commercial viability depends on Lytenava for wet AMD.

CervoMed owns the neflamapimod program itself; the company is described as developing treatments for age-related brain disorders and is advancing a higher-dose regimen in future trials.

Anika's core products are HA joint injections, so its revenue is highly sensitive to procedure volumes, payer restrictions, and reimbursement economics.

Sabra has a substantial triple-net skilled-nursing portfolio; its rental cash flow depends on operator occupancy, labor conditions and reimbursement-supported rent coverage.

LTC invests in skilled-nursing and senior-housing properties, so its rent collection and asset values depend materially on operator economics.

Strawberry Fields receives substantially all revenue from long-term triple-net leases on skilled-nursing and related properties, leaving it indirectly exposed to tenant operating cash flow.

Welltower is primarily a healthcare landlord and benefits from retained rental income, but its operator and tenant economics remain exposed to labor costs and care-fee adequacy.

EyePoint's DURAVYU program is a sustained-delivery retinal therapy for wet AMD, creating substantial indication exposure despite its broader pipeline.

4D Molecular Therapeutics' 4D-150 is a late-stage investigational gene therapy for wet AMD, making its enterprise value materially connected to the same treatment market.

Novartis has NIO752, a MAPT-targeting antisense program being evaluated in Alzheimer’s disease and progressive supranuclear palsy.

Attendo's Finnish care-home economics can benefit from higher occupancy and demographic demand, although contract terminations and pricing pressure create offsetting risks.

Aedifica has a direct, evidenced ability to acquire and develop Finnish healthcare properties, making it one of the clearest potential asset-side beneficiaries of additional care-property supply.

AK Medical Holdings Limited, an investment holding enterprise, specializes in the research, development, production, and worldwide commercialization of orthopedic joint implants and related medical devices under the AK Medical brand. Its comprehensive product offerings encompass conventional knee, hip, and spine replacement implants, as well as advanced 3D-printed solutions like hip implants, artificial vertebral bodies, and spinal interbody cages. The company further expands its operations by distributing orthopedic products from third-party manufacturers and by fabricating surgical instruments and medical irrigators. Its diverse client base spans distributors, hospitals, physicians, surgeons, and directly serves patients. Established in Beijing, People's Republic of China, in 2003, AK Medical Holdings Limited functions as a subsidiary of Ximalaya Limited.

United Orthopedic Corporation is a firm dedicated to the research, development, manufacturing, and global distribution of advanced orthopedic implants and specialized surgical instruments. The company's extensive product offerings address a wide spectrum of orthopedic needs. Its comprehensive range of hip and knee solutions includes various artificial hip joints, partial hip replacements, specialized joints for large trochanteric fractures, and Moore hip prostheses. Uniquely, it also designs and supplies custom artificial hip and knee joints specifically tailored for individual tumor patients, alongside standard artificial knee replacement joints, revision systems, and restricted artificial knee joints. For spinal care, United Orthopedic manufactures vertebral fixation devices. Furthermore, its portfolio extends to injury and trauma products, which encompass a variety of orthopedic internal fixation items, bone plates, bone nails, bone pins, and bone screws. The company also functions as an OEM supplier for orthopedic internal fixation solutions and provides specialized lamb salvage systems. Beyond implants, United Orthopedic Corporation delivers orthopedic surgical equipment and the machinery necessary for its manufacturing. It also trades in special metal and plastic materials, actively engaging in the import and export of its products across international markets. With a global footprint, the company conducts business in Taiwan, across Asia, the Americas, Europe, Africa, and Australia. Established in 1993, United Orthopedic Corporation is headquartered in New Taipei City, Taiwan, and operates as a subsidiary of Chi-Yi Investment Co. Ltd.

Globus has high orthopedic overlap in spine, but less overlap in hips and knees than the core joint-replacement competitors.

Globus Medical is a pure-play musculoskeletal and spine technology company. Although its overlap is greater in spine than in hips and knees, a more nimble DePuy Synthes could compete for surgeon relationships, hospital accounts, orthopedic technology investment, and specialized-device share.

Significant overlap in reconstructive implants but smaller relative scale and focused on specific niches.

Enovis is a smaller musculoskeletal and joint-replacement challenger. A more focused DePuy Synthes could intensify competition for orthopedic portfolio breadth, surgeon attention, hospital contracts, and enabling-technology investment, although Enovis has less direct overlap than the major hip-and-knee leaders.

Belite owns tinlarebant, an investigational oral therapy specifically for STGD1, and has filed applications in three additional countries.

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

Kodiak has investigational wet AMD and retinal durability programs, giving it material exposure to the same treatment market.

Ocular’s long-acting intravitreal wet AMD program is commercially adjacent, but its causal exposure is less direct than that of same-modality gene-therapy developers.

Ocular is developing AXPAXLI, another long-acting intravitreal wet AMD therapy. DAYBREAK could increase competitive and regulatory pressure in the sustained-delivery segment, even though a successful result would also validate demand for reduced injection frequency.

Ventas owns healthcare and senior-living real estate and can benefit from sector rental and valuation demand, but operator labor and rent-cover pressure constrain the pass-through.

Healthcare and senior-living operators in Ventas's portfolio depend on direct-care workers, including nursing assistants and home-health aides. The retrieved evidence indicates that thousands of Haitian TPS holders work as nursing assistants or caregivers, so broader work-authorization losses can increase agency staffing, overtime, vacancies, bed closures, and operator labor costs, pressuring rent coverage and property-level cash flow.

Omega is a landlord exposed indirectly through operator rent coverage; labor-intensive care operations can weaken tenant cash flow and constrain sustainable rents.

Omega Healthcare Investors, Inc. functions as a Real Estate Investment Trust (REIT) primarily focused on the long-term healthcare sector. The company strategically invests in properties providing skilled nursing and assisted living services. A diverse array of healthcare operators manage these assets, predominantly utilizing a triple-net lease framework. Its portfolio is geographically distributed across all regions of the United States and also includes holdings in the United Kingdom.

NHI has skilled-nursing lease exposure and depends on tenant credit and rent coverage, but the evidenced role is landlord rather than operator.

Established in 1991, National Health Investors, Inc. (NYSE: NHI) operates as a real estate investment trust (REIT) primarily focused on providing capital for senior living and medical real estate assets. The company facilitates this through diverse financing options, including sale-leaseback arrangements, joint ventures, and various debt instruments such as mortgage and mezzanine loans, targeting properties that cater to both essential care needs and discretionary services. NHI's broad holdings feature independent living, assisted living, and memory care facilities, as well as entrance-fee retirement communities, skilled nursing homes, medical office complexes, and specialized hospitals.

Impact Healthcare REIT captures landlord rental income, but its tenant economics remain exposed to staffing costs and regulated fees that may not rise as quickly as indexed rents.

AHR has senior-housing exposure but is more diversified than the SNF-focused landlords; its direct operating sensitivity is therefore lower, while property valuation still reflects care-sector risks.

American Healthcare REIT (AHR) was forged through a significant strategic consolidation, combining Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, along with integrating the business and operations of American Healthcare Investors. This comprehensive merger has established AHR as a leading global real estate investment trust focused on healthcare properties, boasting an impressive portfolio with a gross investment value of approximately $4.2 billion. A core strength of the company lies in its fully integrated management platform, staffed by over one hundred highly experienced and proficient professionals. Many members of this team have a long history of collaboration, dating back to 2006, and have successfully invested in and overseen healthcare real estate assets across diverse market cycles. Their collective expertise, extensive industry network, and deep, firsthand understanding of each property within the international portfolio – which they have meticulously built and managed since its first acquisition in 2014 – are unparalleled. This powerful combination of a robust management team and a high-quality asset base strategically positions American Healthcare REIT to capitalize on compelling growth opportunities, driven by significant demographic trends. Its expansive portfolio encompasses 19 million square feet across 312 distinct properties, including medical office buildings, senior housing communities, skilled nursing facilities, and integrated senior health campuses. This diverse collection is strategically distributed across 36 U.S. states and the United Kingdom. The aforementioned tri-party transaction represented a pivotal step in ideally preparing American Healthcare REIT for a future public listing or Initial Public Offering (IPO) on a national stock exchange when market conditions are most favorable. By eventually listing its shares, the company anticipates gaining enhanced access to attractive capital sources, which will be crucial for fueling future expansion, diversifying its investor base, and providing greater liquidity for its existing stockholders. American Healthcare REIT, Inc. operates as a subsidiary of Griffin Capital Company, LLC.

Target benefits from care-property rent and premium private-pay demand, but tenant profitability and rent coverage remain sensitive to staffing costs and public funding.

Voya’s evidenced revenue base includes retirement recordkeeping, asset management, insurance premiums, and advisory services, establishing complete overlap with the factor.

Retirement and protection products are long-term security assets and are viewed as highly inelastic.

As Social Security's retirement fund depletion timeline accelerates, consumer anxiety regarding guaranteed lifetime income is rising. This creates a strong tailwind for private retirement solutions and annuities. Prudential, as a market leader in longevity risk transfer and retirement income products, is uniquely positioned to capture this demand from near-retirees looking to secure alternative lifetime income.

Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermore, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.

EssilorLuxottica has a direct OTC hearing-glasses product, so it can capture demand from the same self-directed channel while facing new competition from Meta.

EssilorLuxottica has a mixed exposure. Meta’s clearance validates the hearing-glasses category and supports demand for the Ray-Ban Meta platform, for which EssilorLuxottica is Meta’s eyewear partner, but Meta’s newly cleared feature also competes with EssilorLuxottica’s Nuance Audio hearing glasses.

Bausch + Lomb is a public ophthalmic medtech and vision-care company exposed to the same provider and diagnostic-equipment ecosystem.

Subretinal gene-therapy procedures require specialized vitrectomy platforms and controlled microinjection equipment. Bausch + Lomb’s Stellaris platform is one of the platforms identified as compatible with subretinal injection devices, creating modest procedure-volume upside as Phase 3 retinal gene therapy expands.

Cochlear's exposure is second-order: prevention of pediatric chemotherapy-related hearing loss could reduce future hearing-device demand.

Globally, Cochlear Limited specializes in the development and provision of implantable auditory solutions for both children and adults. The company's diverse offerings include advanced cochlear implant systems, upgrades for sound processors, bone conduction devices, and a wide array of accessories and other related items. Established in 1981, its global operations are directed from its headquarters in Sydney, Australia.

BioVie owns bezisterim, the investigational therapy being advanced for Long COVID fatigue and cognitive symptoms, creating direct therapeutic exposure.